"Luminal A breast cancer" trang 1 - tải miễn phí từ tailieunhanh
Androgen receptor and FOXA1 coexpression define a “luminal-AR” subtype of feline mammary carcinomas, spontaneous models of breast cancer

Androgen receptor and FOXA1 coexpression define a “luminal-AR” subtype of feline mammary carcinomas, spontaneous models of breast cancer
16    81    0
Promoter methylation of transient receptor potential melastatin-related 7 (TRPM7) predicts a better prognosis in patients with Luminal A breast cancers

Promoter methylation of transient receptor potential melastatin-related 7 (TRPM7) predicts a better prognosis in patients with Luminal A breast cancers
10    1    1
Identification of differentially expressed lncRNAs and mRNAs in luminal-B breast cancer by RNA-sequencing

Identification of differentially expressed lncRNAs and mRNAs in luminal-B breast cancer by RNA-sequencing
12    99    0
PLC-gamma-1 phosphorylation status is prognostic of metastatic risk in patients with early-stage Luminal-A and -B breast cancer subtypes

PLC-gamma-1 phosphorylation status is prognostic of metastatic risk in patients with early-stage Luminal-A and -B breast cancer subtypes
10    84    0
The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer

The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer
10    71    1
Identification of methylation sites and signature genes with prognostic value for luminal breast cancer

Identification of methylation sites and signature genes with prognostic value for luminal breast cancer
13    32    1
Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer

Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer
7    31    1
St Gallen molecular subtypes in primary breast cancer and matched lymph node metastases - aspects on distribution and prognosis for patients with luminal A tumours: Results from a prospective randomised trial

St Gallen molecular subtypes in primary breast cancer and matched lymph node metastases - aspects on distribution and prognosis for patients with luminal A tumours: Results from a prospective randomised trial
10    41    1
Neo-CheckRay: Radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial

Neo-CheckRay: Radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial
9    59    1
Nomograms predict survival of patients with lymph node-positive, luminal a breast cancer

Nomograms predict survival of patients with lymph node-positive, luminal a breast cancer
17    34    1
Characteristics and chronologically changing patterns of late-onset breast cancer in Korean women of age≥70years: A hospital based-registry study

Characteristics and chronologically changing patterns of late-onset breast cancer in Korean women of age≥70years: A hospital based-registry study
15    1    1
Inhibition of SHP2 in basal-like and triple-negative breast cells induces basal-to-luminal transition, hormone dependency, and sensitivity to anti-hormone treatment

Inhibition of SHP2 in basal-like and triple-negative breast cells induces basal-to-luminal transition, hormone dependency, and sensitivity to anti-hormone treatment
12    34    1
BC200 overexpression contributes to luminal and triple negative breast cancer pathogenesis

BC200 overexpression contributes to luminal and triple negative breast cancer pathogenesis
17    78    0
Active behavior of triple-negative breast cancer with adipose tissue invasion: A single center and retrospective review

Active behavior of triple-negative breast cancer with adipose tissue invasion: A single center and retrospective review
11    37    1
PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer

PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer
8    80    0
Apparent diffusion coefficient cannot predict molecular subtype and lymph node metastases in invasive breast cancer: A multicenter analysis

Apparent diffusion coefficient cannot predict molecular subtype and lymph node metastases in invasive breast cancer: A multicenter analysis
8    79    0
Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy

Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy
9    90    0
Circulating microRNAs miR-331 and miR195 differentiate local luminal a from metastatic breast cancer

Circulating microRNAs miR-331 and miR195 differentiate local luminal a from metastatic breast cancer
10    80    0
Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy

Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy
13    40    1
IL-1β induces IL-6 production and increases invasiveness and estrogen-independent growth in a TG2-dependent manner in human breast cancer cells

IL-1β induces IL-6 production and increases invasiveness and estrogen-independent growth in a TG2-dependent manner in human breast cancer cells
11    31    1